{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:57:32Z","timestamp":1770836252262,"version":"3.50.1"},"reference-count":144,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","jpain.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pain"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jpain.2022.05.003","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T22:50:23Z","timestamp":1653519023000},"page":"1666-1679","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["If the Doors of Perception Were Cleansed, Would Chronic Pain be Relieved? Evaluating the Benefits and Risks of Psychedelics"],"prefix":"10.1016","volume":"23","author":[{"given":"Robert H.","family":"Dworkin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5023-660X","authenticated-orcid":false,"given":"Brian T.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9966-5093","authenticated-orcid":false,"given":"Nick","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4873-0443","authenticated-orcid":false,"given":"Robert R.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles S.","family":"Grob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Ross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7072-9399","authenticated-orcid":false,"given":"Theodore D.","family":"Satterthwaite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8482-5461","authenticated-orcid":false,"given":"Eric C.","family":"Strain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpain.2022.05.003_bib0001","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1021\/acsptsci.1c00014","article-title":"Predicting reactions to psychedelic drugs: A systematic review of states and traits related to acute drug effects","volume":"4","author":"Aday","year":"2021","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.jpain.2022.05.003_bib0002","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-022-06123-7","article-title":"Great expectations: Recommendations for improving the methodological rigor of psychedelic clinical trials","author":"Aday","year":"2022","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jpain.2022.05.003_bib0003","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/0269881119897615","article-title":"Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer","volume":"34","author":"Agin-Liebes","year":"2020","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.jpain.2022.05.003_bib0004","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.tips.2021.08.003","article-title":"Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics","volume":"42","author":"Aleksandrova","year":"2021","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jpain.2022.05.003_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100538","article-title":"Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study","volume":"27","author":"Anderson","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jpain.2022.05.003_bib0006","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2215-0366(20)30146-2","article-title":"Psychedelic medicine: Safety and ethical concerns","volume":"7","author":"Anderson","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jpain.2022.05.003_bib0007","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12954-017-0186-6","article-title":"Psychoactive substances as a last resort: A qualitative study of self-treatment of migraine and cluster headaches","volume":"14","author":"Andersson","year":"2017","journal-title":"Harm Reduct J"},{"key":"10.1016\/j.jpain.2022.05.003_bib0008","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1001\/jamapsychiatry.2013.3469","article-title":"Disruption of cortical association networks in schizophrenia and psychotic bipolar disorder","volume":"71","author":"Baker","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jpain.2022.05.003_bib0009","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1038\/s41598-020-59282-y","article-title":"Emotions and brain function are altered up to one month after a single high dose of psilocybin","volume":"10","author":"Barrett","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jpain.2022.05.003_bib0010","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/7854_2017_474","article-title":"Classic hallucinogens and mystical experiences: Phenomenology and neural correlates","volume":"36","author":"Barrett","year":"2018","journal-title":"Curr Top Behav Neurosci"},{"key":"10.1016\/j.jpain.2022.05.003_bib0011","first-page":"742","article-title":"Understanding the emergence of neuropsychiatric disorders with network neuroscience","volume":"3","author":"Bassett","year":"2018","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"10.1016\/j.jpain.2022.05.003_bib0012","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.neuropharm.2018.02.018","article-title":"Psychedelics: Where we are now, why we got here, what we must do","volume":"142","author":"Belouin","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jpain.2022.05.003_bib0013","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.jpain.2022.05.003_bib0014","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/7854_2016_464","article-title":"Therapeutic applications of classic hallucinogens","volume":"36","author":"Bogenshutz","year":"2018","journal-title":"Curr Topics Behav Neurosci"},{"key":"10.1016\/j.jpain.2022.05.003_bib0015","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00213-017-4777-4","article-title":"Regulation of human research with LSD in the United States (1949-1987)","volume":"235","author":"Bonson","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jpain.2022.05.003_bib0016","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0893-133X(95)00145-4","article-title":"Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans","volume":"14","author":"Bonson","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpain.2022.05.003_bib0017","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0166-4328(96)00102-7","article-title":"Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium","volume":"73","author":"Bonson","year":"1996","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.jpain.2022.05.003_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1196\/annals.1440.011","article-title":"The brain's default network: Anatomy, function, and relevance to disease","volume":"1124","author":"Buckner","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jpain.2022.05.003_bib0019","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1097\/j.pain.0000000000001937","article-title":"Estimands and missing data in clinical trials of chronic pain treatments: Advances in design and analysis","volume":"161","author":"Cai","year":"2020","journal-title":"Pain"},{"key":"10.1016\/j.jpain.2022.05.003_bib0020","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.neuropharm.2017.11.028","article-title":"A regulatory perspective on the evaluation of hallucinogen drugs for human use","volume":"142","author":"Calderon","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jpain.2022.05.003_bib0021","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-045105","article-title":"SPIRIT-PRO extension explanation and elaboration: Guidelines for inclusion of patient-reported outcomes in protocols of clinical trials","volume":"11","author":"Calvert","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.jpain.2022.05.003_bib0022","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1177\/0269881116662634","article-title":"Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative experiences","volume":"30","author":"Carbonaro","year":"2016","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.jpain.2022.05.003_bib0023","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1007\/s00213-020-05533-9","article-title":"Subjective features of the psilocybin experience that may account for its self-administration by humans: A double-blind comparison of psilocybin and dextromethorphan","volume":"237","author":"Carbonaro","year":"2020","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jpain.2022.05.003_bib0024","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00213-017-4769-4","article-title":"Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: Similarities and differences in subjective experiences","volume":"235","author":"Carbonaro","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jpain.2022.05.003_bib0025","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpain.2022.05.003_bib0026","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jpain.2022.05.003_bib0027","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jpain.2022.05.003_bib0028","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00213-017-4701-y","article-title":"Psychedelics and connectedness","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jpain.2022.05.003_bib0029","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1177\/0269881118754710","article-title":"Psychedelics and the essential importance of context","volume":"32","author":"Carhart-Harris","year":"2018","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.jpain.2022.05.003_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.739053","article-title":"The effects of tryptamine psychedelics in the brain: A meta-analysis of functional and review of molecular imaging studies","volume":"12","author":"Castelhano","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jpain.2022.05.003_bib0031","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1136\/rapm-2020-101273","article-title":"Chronic pain and psychedelics: A review and proposed mechanism of action","volume":"45","author":"Castellanos","year":"2020","journal-title":"Reg Anesth Pain Med"},{"key":"10.1016\/j.jpain.2022.05.003_bib0032","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/s43587-021-00125-4","article-title":"Long-term prognosis and educational determinants of brain network decline in older adult individuals","volume":"1","author":"Chan","year":"2021","journal-title":"Nat Aging"},{"key":"10.1016\/j.jpain.2022.05.003_bib0033","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S1470-2045(19)30790-9","article-title":"International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: Recommendations of the SISAQOL Consortium","volume":"21","author":"Coens","year":"2020","journal-title":"Lancet Oncology"},{"key":"10.1016\/j.jpain.2022.05.003_bib0034","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2174\/1570159X15666170911121027","article-title":"Review: 5-HT1, 5-HT2, 5-HT3 and 5-HT7 receptors and their role in the modulation of pain responses in the central nervous system","volume":"16","author":"Cortes-Altamirano","year":"2018","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.jpain.2022.05.003_bib0035","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.neuropharm.2018.01.005","article-title":"A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study","volume":"142","author":"Dakwar","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jpain.2022.05.003_bib0036","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jpain.2022.05.003_bib0037","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-022-01744-z","article-title":"Increased global integration in the brain after psilocybin therapy for depression","author":"Daws","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jpain.2022.05.003_bib0038","series-title":"Visionary Vine: Psychedelic Healing in the Peruvian Amazon","author":"Dobkin de Rios","year":"1972"},{"key":"10.1016\/j.jpain.2022.05.003_bib0039","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/17512433.2018.1511424","article-title":"Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: A systematic review of systematic reviews","volume":"11","author":"dos Santos","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jpain.2022.05.003_bib0040","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.neubiorev.2016.10.026","article-title":"Classical hallucinogens and neuroimaging: A systematic review of human studies","volume":"71","author":"dos Santos","year":"2016","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.jpain.2022.05.003_bib0041","doi-asserted-by":"crossref","first-page":"e863","DOI":"10.1097\/PR9.0000000000000863","article-title":"Essential statistical principles of clinical trials of pain treatments","volume":"6","author":"Dworkin","year":"2021","journal-title":"Pain Rep"},{"key":"10.1016\/j.jpain.2022.05.003_bib0042","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.pain.2004.09.012","article-title":"Core outcome measures for chronic pain clinical trials: IMMPACT recommendations","volume":"113","author":"Dworkin","year":"2005","journal-title":"Pain"},{"key":"10.1016\/j.jpain.2022.05.003_bib0043","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pain.2010.02.018","article-title":"Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations","volume":"149","author":"Dworkin","year":"2010","journal-title":"Pain"},{"key":"10.1016\/j.jpain.2022.05.003_bib0044","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.pain.2012.03.003","article-title":"Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations","volume":"153","author":"Dworkin","year":"2012","journal-title":"Pain"},{"key":"10.1016\/j.jpain.2022.05.003_bib0045","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/0269881121997099","article-title":"Cannabis-induced oceanic boundlessness","volume":"35","author":"Earleywine","year":"2021","journal-title":"J Psychopharmacol"},{"issue":"2","key":"10.1016\/j.jpain.2022.05.003_bib0046","doi-asserted-by":"crossref","first-page":"T70","DOI":"10.1016\/j.jpain.2016.01.001","article-title":"The role of psychosocial processes in the development and maintenance of chronic pain","volume":"17","author":"Edwards","year":"2016","journal-title":"J Pain"},{"key":"10.1016\/j.jpain.2022.05.003_bib0047","unstructured":"Erowid Experience Vaults: For the pain of fibromyalgia. Available at: erowid.org\/experiences\/exp.php?ID=68760. Accessed February 3, 2022"},{"key":"10.1016\/j.jpain.2022.05.003_bib0048","series-title":"The Psychedelic Explorer's Guide: Safe, Therapeutic, and Sacred Journeys","author":"Fadiman","year":"2011"},{"key":"10.1016\/j.jpain.2022.05.003_bib0049","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/09540261.2018.1481827","article-title":"Psychedelics as anti-inflammatory agents","volume":"30","author":"Flanagan","year":"2018","journal-title":"Int Rev Psychiatry"},{"key":"10.1016\/j.jpain.2022.05.003_bib0050","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jclinepi.2019.02.011","article-title":"The selection of comparators for randomized controlled trials of health-related behavioral interventions: Recommendations of an NIH expert panel","volume":"110","author":"Freedland","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jpain.2022.05.003_bib0051","series-title":"Hallucinogens and Culture","author":"Furst","year":"1976"},{"key":"10.1016\/j.jpain.2022.05.003_bib0052","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","article-title":"Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases","volume":"202","author":"Gasser","year":"2014","journal-title":"J Nerv Ment Dis"},{"key":"10.1016\/j.jpain.2022.05.003_bib0053","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0269881114555249","article-title":"LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained effects","volume":"29","author":"Gasser","year":"2015","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.jpain.2022.05.003_bib0054","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.pain.2014.05.025","article-title":"Research design considerations for proof-of-concept chronic pain clinical trials: IMMPACT recommendations","volume":"155","author":"Gewandter","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.jpain.2022.05.003_bib0055","doi-asserted-by":"crossref","first-page":"e621","DOI":"10.1097\/PR9.0000000000000621","article-title":"Checklist for the preparation and review of pain clinical trial publications: A pain-specific supplement to CONSORT","volume":"4","author":"Gewandter","year":"2019","journal-title":"Pain Rep"},{"key":"10.1016\/j.jpain.2022.05.003_bib0056","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1097\/j.pain.0000000000002283","article-title":"Research approaches for evaluating opioid sparing in clinical trials of acute and chronic pain treatments: Initiative on methods, measurement, and pain assessment in clinical trials recommendations","volume":"162","author":"Gewandter","year":"2021","journal-title":"Pain"},{"key":"10.1016\/j.jpain.2022.05.003_bib0057","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1055\/s-2007-979356","article-title":"Methodological issues of human experimental research with hallucinogens","volume":"31","author":"Gouzoulis-Mayfrank","year":"1998","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jpain.2022.05.003_bib0058","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.jpain.2022.05.003_bib0059","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jpain.2022.05.003_bib0060","series-title":"Handbook of Medical Hallucinogens","author":"Grob","year":"2021"},{"key":"10.1016\/j.jpain.2022.05.003_bib0061","series-title":"Realms of the Human Unconscious: Observations from LSD Research","author":"Grof","year":"1976"},{"key":"10.1016\/j.jpain.2022.05.003_bib0062","series-title":"Hallucinogens and Shamanism","author":"Harner","year":"1973"},{"key":"10.1016\/j.jpain.2022.05.003_bib0063","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1001\/jamapsychiatry.2019.1145","article-title":"Disruptive psychopharmacology","volume":"76","author":"Heifets","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jpain.2022.05.003_bib0064","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/17448069211043965","article-title":"A systematic review on descending serotonergic projections and modulation of spinal nociception in chronic neuropathic pain and after spinal cord stimulation","volume":"17","author":"Heijmans","year":"2021","journal-title":"Mol Pain"},{"key":"10.1016\/j.jpain.2022.05.003_bib0065","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1021\/acschemneuro.9b00493","article-title":"Psychedelics, but not ketamine, produce persistent antidepressant-like effects in a rodent experimental system for the study of depression","volume":"11","author":"Hibicke","year":"2020","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.jpain.2022.05.003_bib0066","doi-asserted-by":"crossref","DOI":"10.1176\/appi.psychotherapy.20200055","article-title":"Systematized review of psychotherapeutic components of psilocybin-assisted psychotherapy","author":"Horton","year":"2021","journal-title":"Am J Psychother"},{"key":"10.1016\/j.jpain.2022.05.003_bib0067","series-title":"The Doors of Perception","author":"Huxley","year":"1954"},{"key":"10.1016\/j.jpain.2022.05.003_bib0068","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1124\/pharmrev.120.000056","article-title":"Psychedelics in psychiatry: Neuroplastic, immunomodulatory, and neurotransmitter mechanisms","volume":"73","author":"Inserra","year":"2021","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jpain.2022.05.003_bib0069","series-title":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use: Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on statistical principles for clinical trials: E9(R1)","year":"2019"},{"key":"10.1016\/j.jpain.2022.05.003_bib0070","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.jpain.2022.05.003_bib0071","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","article-title":"The abuse potential of medical psilocybin according to the 8 factors of the controlled substances act","volume":"142","author":"Johnson","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jpain.2022.05.003_bib0072","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pharmthera.2018.11.010","article-title":"Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function","volume":"197","author":"Johnson","year":"2019","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jpain.2022.05.003_bib0073","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: Guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.jpain.2022.05.003_bib0074","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1177\/0333102410363490","article-title":"The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: An open, non-randomized case series","volume":"30","author":"Karst","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1016\/j.jpain.2022.05.003_bib0075","series-title":"LSD: The Consciousness Expanding Drug","first-page":"239","article-title":"Pain and LSD-25: A theory of attenuation of anticipation","author":"Kast","year":"1966"},{"key":"10.1016\/j.jpain.2022.05.003_bib0076","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1007\/BF01575629","article-title":"Attenuation of anticipation: A therapeutic use of lysergic acid diethylamide","volume":"41","author":"Kast","year":"1967","journal-title":"Psychiatr Q"},{"key":"10.1016\/j.jpain.2022.05.003_bib0077","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1213\/00000539-196405000-00013","article-title":"Study of lysergic acid diethylamide as an analgesic agent","volume":"43","author":"Kast","year":"1964","journal-title":"Anesth Analg"},{"key":"10.1016\/j.jpain.2022.05.003_bib0078","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1097\/j.pain.0000000000002204","volume":"162","author":"Katz","year":"2021","journal-title":"Pain"},{"key":"10.1016\/j.jpain.2022.05.003_bib0079","article-title":"Psychedelics for brain injury: A mini-review","volume":"29","author":"Khan","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.jpain.2022.05.003_bib0080","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1097\/j.pain.0000000000002475","article-title":"Benefit-risk assessment and reporting in clinical trials of chronic pain treatments: IMMPACT recommendations","volume":"163","author":"Kleykamp","year":"2022","journal-title":"Pain"},{"key":"10.1016\/j.jpain.2022.05.003_bib0081","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1177\/0269881112439253","article-title":"Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized trials","volume":"26","author":"Krebs","year":"2012","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.jpain.2022.05.003_bib0082","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.tips.2017.08.003","article-title":"Psychedelic drugs in biomedicine","volume":"38","author":"Kyzar","year":"2017","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jpain.2022.05.003_bib0083","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1097\/j.pain.0000000000001254","article-title":"Reproducible and replicable pain research: A critical review","volume":"159","author":"Lee","year":"2018","journal-title":"Pain"},{"key":"10.1016\/j.jpain.2022.05.003_bib0084","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1056\/NEJMe2102835","article-title":"Back to the future: The therapeutic potential of psychedelic drugs","volume":"384","author":"Leiberman","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpain.2022.05.003_bib0085","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1177\/0269881118793086","article-title":"Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016","volume":"32","author":"Leonard","year":"2018","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.jpain.2022.05.003_bib0086","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuroimage.2020.117653","article-title":"LSD alters dynamic integration and segregation in the human brain","volume":"227","author":"Luppi","year":"2021","journal-title":"NeuroImage"},{"key":"10.1016\/j.jpain.2022.05.003_bib0087","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","article-title":"Psychedelics promote structural and functional plasticity","volume":"23","author":"Ly","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.jpain.2022.05.003_bib0088","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.euroneuro.2021.06.001","article-title":"Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience","volume":"50","author":"Madsen","year":"2021","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.jpain.2022.05.003_bib0089","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1038\/s41386-020-0718-8","article-title":"Me, myself, and bye: Regional alterations in glutamate and the experience of ego dissolution with psilocybin","volume":"45","author":"Mason","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpain.2022.05.003_bib0090","series-title":"The Varieties of Psychedelic Experience","author":"Masters","year":"1966"},{"key":"10.1016\/j.jpain.2022.05.003_bib0091","article-title":"Psychedelic resting-state neuroimaging: A review and perspective on balancing replication and novel analyses","author":"McCulloch","year":"2021","journal-title":"PsyArXiv"},{"key":"10.1016\/j.jpain.2022.05.003_bib0092","series-title":"The Ecstatic Adventure","year":"1968"},{"key":"10.1016\/j.jpain.2022.05.003_bib0093","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jpain.2022.05.003_bib0094","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S2215-0366(15)00576-3","article-title":"Novel psychopharmacological therapies for psychiatric disorders: Psilocybin and MDMA","volume":"3","author":"Mithoefer","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jpain.2022.05.003_bib0095","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/bs.pbr.2018.08.003","article-title":"The renaissance in psychedelic research: What do preclinical models have to offer","volume":"242","author":"Murnane","year":"2018","journal-title":"Prog Brain Res"},{"key":"10.1016\/j.jpain.2022.05.003_bib0096","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/17512433.2021.1933434","article-title":"Blinding and expectancy confounds in psychedelic randomized controlled trials","volume":"14","author":"Muthukumaraswamy","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jpain.2022.05.003_bib0097","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1055\/a-1312-7297","article-title":"Psychedelics and psychotherapy","volume":"54","author":"Nayak","year":"2021","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jpain.2022.05.003_bib0098","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jpain.2022.05.003_bib0099","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/cpt.557","article-title":"Psychedelics as medicines: An emerging new paradigm","volume":"101","author":"Nichols","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpain.2022.05.003_bib0100","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1086\/383628","article-title":"LSD before Leary: Sidney Cohen's critique of 1950s psychedelic drug research","volume":"88","author":"Novak","year":"1997","journal-title":"Isis"},{"key":"10.1016\/j.jpain.2022.05.003_bib0101","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1001\/jamapsychiatry.2020.2171","article-title":"The current status of psychedelics in psychiatry","volume":"78","author":"Nutt","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jpain.2022.05.003_bib0102","series-title":"Fifty Years of LSD: Current Status and Perspectives of Hallucinogens","first-page":"213","article-title":"Methodologic issues in the evaluation of a medication for its potential benefits in enhancing psychotherapy","author":"O'Brien","year":"1994"},{"key":"10.1016\/j.jpain.2022.05.003_bib0103","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1021\/acsptsci.0c00192","article-title":"The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects","volume":"4","author":"Olson","year":"2021","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.jpain.2022.05.003_bib0104","unstructured":"Oregon Health Authority Prevention and Wellness Public Health Division: Oregon psilocybin services. Available at: www.oregon.gov\/oha\/PH\/PREVENTIONWELLNESS\/Pages\/Oregon-Psilocybin-Services.aspx. Accessed February 3, 2022"},{"key":"10.1016\/j.jpain.2022.05.003_bib0105","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1017\/S0033291718001356","article-title":"Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomized placebo-controlled trial","volume":"49","author":"Palhano-Fontes","year":"2019","journal-title":"Psychol Med"},{"key":"10.1016\/j.jpain.2022.05.003_bib0106","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.3389\/fpsyg.2020.01681","article-title":"Psychedelic research and the need for transparency: Polishing Alice's looking glass","volume":"11","author":"Petranker","year":"2020","journal-title":"Front Psychol"},{"key":"10.1016\/j.jpain.2022.05.003_bib0107","article-title":"Dissociable multi-scale patterns of development in personalized brain networks","author":"Pines","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.jpain.2022.05.003_bib0108","series-title":"How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence","author":"Pollan","year":"2018"},{"key":"10.1016\/j.jpain.2022.05.003_bib0109","series-title":"This is Your Mind on Plants","author":"Pollan","year":"2021"},{"key":"10.1016\/j.jpain.2022.05.003_bib0110","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/0269881120940937","article-title":"A low dose of lysergic acid diethylamide decrease pain perception in healthy volunteers","volume":"35","author":"Raemekers","year":"2021","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.jpain.2022.05.003_bib0111","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/13554794.2018.1468469","article-title":"Relief from intractable phantom pain by combining psilocybin and mirror visual-feedback (MVF)","volume":"24","author":"Ramachandran","year":"2018","journal-title":"Neurocase"},{"key":"10.1016\/j.jpain.2022.05.003_bib0112","doi-asserted-by":"crossref","first-page":"e9019","DOI":"10.1371\/journal.pone.0009019","article-title":"Psychedelics and the human receptorome","volume":"5","author":"Ray","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jpain.2022.05.003_bib0113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pnpbp.2017.09.012","article-title":"Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review","volume":"81","author":"Reiche","year":"2018","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.jpain.2022.05.003_bib0114","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2174\/15680266113139990039","article-title":"Predictive in silico studies of human 5-hydroxytryptamine receptor subtype 2B (5-HT2b) and valvular heart disease","volume":"13","author":"Reid","year":"2013","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.jpain.2022.05.003_bib0115","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1176\/appi.ajp.2019.19010035","article-title":"Psychedelics and psychedelic-assisted psychotherapy","volume":"177","author":"Reiff","year":"2020","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jpain.2022.05.003_bib0116","series-title":"Sacred Knowledge: Psychedelics and Religious Experiences","author":"Richards","year":"2016"},{"key":"10.1016\/j.jpain.2022.05.003_bib0117","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jpsychires.2021.03.002","article-title":"Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review","volume":"137","author":"Romeo","year":"2021","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.jpain.2022.05.003_bib0118","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/09540261.2018.1482261","article-title":"Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress","volume":"30","author":"Ross","year":"2018","journal-title":"Int Rev Psychiatry"},{"key":"10.1016\/j.jpain.2022.05.003_bib0119","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1021\/acsptsci.1c00020","article-title":"Acute and sustained reductions in loss of meaning and suicidal ideation following psilocybin-assisted psychotherapy for psychiatric and existential distress in life-threatening cancer","volume":"4","author":"Ross","year":"2021","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.jpain.2022.05.003_bib0120","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.jpain.2022.05.003_bib0121","doi-asserted-by":"crossref","first-page":"11934","DOI":"10.1073\/pnas.182234399","article-title":"Salvinorin A: A potent naturally occurring nonnitrogenous kappa opioid selective agonist","volume":"99","author":"Roth","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jpain.2022.05.003_bib0122","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.conb.2014.10.005","article-title":"How can studies of resting-state functional connectivity help us understand psychosis as a disorder of brain development?","volume":"30","author":"Satterthwaite","year":"2015","journal-title":"Curr Opin Neurobiol"},{"key":"10.1016\/j.jpain.2022.05.003_bib0123","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1002\/hbm.23665","article-title":"Motion artifact in studies of functional connectivity: Characteristics and mitigation strategies","volume":"40","author":"Satterthwaite","year":"2019","journal-title":"Hum Brain Mapp"},{"key":"10.1016\/j.jpain.2022.05.003_bib0124","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1176\/appi.ajp.2020.20030272","article-title":"Some comments on psychedelic research","volume":"177","author":"Schatzberg","year":"2020","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jpain.2022.05.003_bib0125","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s13311-020-00962-y","article-title":"Exploratory controlled study of the migraine-suppressing effects of psilocybin","volume":"18","author":"Schindler","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jpain.2022.05.003_bib0126","series-title":"The Therapeutic Use of Ayahuasca","first-page":"77","article-title":"Healing with ayahuasca: Notes on therapeutic rituals and effects in European patients treating their diseases","author":"Schmid","year":"2020"},{"key":"10.1016\/j.jpain.2022.05.003_bib0127","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/cpt.776","article-title":"Psychedelic drugs as therapeutics: No illusions about the challenges","volume":"103","author":"Sellers","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpain.2022.05.003_bib0128","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.neuropharm.2017.11.029","article-title":"Studies with psychedelic drugs in human volunteers","volume":"142","author":"Sellers","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jpain.2022.05.003_bib0129","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1097\/j.pain.0000000000001952","article-title":"Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations","volume":"161","author":"Smith","year":"2020","journal-title":"Pain"},{"issue":"suppl 1","key":"10.1016\/j.jpain.2022.05.003_bib0130","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/j.pain.0000000000001849","article-title":"Loeser award lecture: Size does matter, but it isn't everything: The challenge of modest treatment effects in chronic pain clinical trials","volume":"161","author":"Smith","year":"2020","journal-title":"Pain"},{"key":"10.1016\/j.jpain.2022.05.003_bib0131","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1001\/jama.2021.12481","article-title":"Two models of legalization of psychedelic substances: Reasons for concern","volume":"326","author":"Smith","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jpain.2022.05.003_bib0132","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0166-4328(96)00081-2","article-title":"Human psychopharmacology of N,N-dimethyltryptamine","volume":"73","author":"Strassman","year":"1995","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.jpain.2022.05.003_bib0133","doi-asserted-by":"crossref","first-page":"e30800","DOI":"10.1371\/journal.pone.0030800","article-title":"Prediction of psilocybin response in healthy volunteers","volume":"7","author":"Studerus","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jpain.2022.05.003_bib0134","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1177\/0269881110382466","article-title":"Acute, subacute and long-term subjective effects of psilocybin in healthy humans: A pooled analysis of experimental studies","volume":"25","author":"Studerus","year":"2011","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.jpain.2022.05.003_bib0135","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1016\/j.neuron.2021.06.016","article-title":"Neurodevelopment of the association cortices: Patterns, mechanisms, and implications for psychopathology","volume":"109","author":"Sydnor","year":"2021","journal-title":"Neuron"},{"key":"10.1016\/j.jpain.2022.05.003_bib0136","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.imlet.2020.10.001","article-title":"Psychedelics as a novel approach to treating autoimmune conditions","volume":"228","author":"Thompson","year":"2020","journal-title":"Immunology Lett"},{"issue":"suppl 2","key":"10.1016\/j.jpain.2022.05.003_bib0137","doi-asserted-by":"crossref","first-page":"T50","DOI":"10.1016\/j.jpain.2016.03.001","article-title":"Toward a mechanism-based approach to pain diagnosis","volume":"17","author":"Vardeh","year":"2016","journal-title":"J Pain"},{"key":"10.1016\/j.jpain.2022.05.003_bib0138","series-title":"The Joyous Cosmology","author":"Watts","year":"1962"},{"key":"10.1016\/j.jpain.2022.05.003_bib0139","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2217\/pmt-2017-0068","article-title":"Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain: A potential role?","volume":"8","author":"Whelan","year":"2018","journal-title":"Pain Manag"},{"key":"10.1016\/j.jpain.2022.05.003_bib0140","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1038\/s41467-018-05317-y","article-title":"Linked dimensions of psychopathology and connectivity in functional brain networks","volume":"9","author":"Xia","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jpain.2022.05.003_bib0141","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1021\/acsptsci.0c00194","article-title":"The subjective effects of psychedelics are necessary for their enduring therapeutic effects","volume":"4","author":"Yaden","year":"2021","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.jpain.2022.05.003_bib0142","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jamapsychiatry.2020.3672","article-title":"Psychedelics in psychiatry: Keeping the renaissance from going off the rails","volume":"78","author":"Yaden","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jpain.2022.05.003_bib0143","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1038\/s41380-018-0201-7","article-title":"Network changes associated with transdiagnostic depressive symptom improvement following cognitive behavioral therapy in MDD and PTSD","volume":"23","author":"Yang","year":"2018","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.jpain.2022.05.003_bib0144","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.2019.9892","article-title":"Harms from uninformative clinical trials","volume":"322","author":"Zarin","year":"2019","journal-title":"JAMA"}],"container-title":["The Journal of Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526590022003297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526590022003297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T16:52:25Z","timestamp":1723567945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526590022003297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":144,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1526590022003297"],"URL":"https:\/\/doi.org\/10.1016\/j.jpain.2022.05.003","relation":{},"ISSN":["1526-5900"],"issn-type":[{"value":"1526-5900","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"If the Doors of Perception Were Cleansed, Would Chronic Pain be Relieved? Evaluating the Benefits and Risks of Psychedelics","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pain","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpain.2022.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc. on behalf of United States Association for the Study of Pain, Inc.","name":"copyright","label":"Copyright"}]}}